Ascletis Pharma Reports Increased Loss and R&D Progress

Ascletis Pharma, Inc. (HK:1672) has released an update.

Ascletis Pharma Inc. has reported a significant increase in loss for the six-month period ending June 30, 2024, compared to the same period in 2023, primarily due to higher research and development costs. The company saw a complete loss of revenue during the period, attributing it to a decrease in market demand for its ritonavir product amidst effective COVID-19 control in Mainland China. Despite financial setbacks, Ascletis Pharma made notable progress in several clinical trials, including positive results for treatments of NASH and acne vulgaris.

For further insights into HK:1672 stock, check out TipRanks’ Stock Analysis page.